Absci Corporation (ABSI)

Several events have impacted Absci's stock price in the past six months. Absci reported a Q1 2026 loss of $0.19 per share, beating estimates, but revenue significantly missed expectations, causing the stock to fall. Positive clinical milestones for ABS-201 were highlighted, including the completion of SAD cohorts and initiation of MAD cohort. Absci announced the addition of ABS-202 to its pipeline and de-emphasized oncology programs to focus on ABS-201. Analyst ratings are mixed, with some maintaining "Buy" ratings while others downgraded the stock. The stock price has been volatile, with a 52-week range between $2.24 and $6.24. There have been insider buying transactions totaling 175,095 shares.

The provided search results do not contain specific information regarding the demand seasonality for Absci Corp.'s products and services. Demand for their services is driven by research and development needs, disease prevalence, and funding availability, rather than predictable seasonal patterns. Clinical trial progress and regulatory milestones are more likely to influence demand.

Absci Corporation is an AI-powered synthetic biology company focused on discovering and developing next-generation therapeutics. They operate in the Healthcare sector, specifically within the Biotechnology industry, using AI-driven drug discovery and synthetic biology. Absci aims to redefine drug discovery by integrating AI technologies with biological systems to create new therapeutics more efficiently. Their core business includes AI-Driven Drug Discovery, which leverages a proprietary AI platform to identify and optimize therapeutic candidates, and Synthetic Biology and Biomanufacturing, which engineers biological systems for the production of complex proteins and biologics. Key programs include ABS-101 for IBD, ABS-201 for androgenetic alopecia and endometriosis, and ABS-202 for an undisclosed inflammation and immunology indication. Absci generates revenue through collaborations, licensing agreements, and service contracts.

Absci Corporation is headquartered in Vancouver, Washington, USA. They also have AI Research Labs in New York City, USA, and Serbia, as well as an Innovation Center in Zug, Switzerland.

Information directly assessing Absci Corp.'s brand reputation is not explicitly available. Positive influences include advancements in its AI platform, strategic collaborations, and progress with ABS-201. Challenges include financial performance, particularly missing revenue estimates, and the deprioritization of oncology programs.

Absci Corporation has significant institutional ownership, with 152 institutional owners holding approximately 77.05% of the shares. Major institutional owners include Fmr Llc, ARK Investment Management LLC, and BlackRock, Inc. Redmile Group LLC is the largest individual shareholder, owning 10.79% of the company.